Global Crohns Disease Diagnostic and Therapeutic Market

Description

Introduction

Crohns disease is a chronic inflammatory disease that can affect any part of the gastrointestinal tract from mouth to anus. The disease can cause significant lifestyle sacrifices and suffering and millions of dollars are spent in related health-care cost every year. The diagnosis of Crohns disease is mainly done through a combination of tests like Tests for anemia or infection and Fecal occult blood test. Currently, there is no cure available for Crohns disease, and there is no one treatment that works for everyone. The medical treatment aims to reduce the inflammation that triggers the signs and symptoms and improve long-term prognosis by limiting complications.

Market Dynamics

The continuous increase in prevalent cases of Crohns Disease across the world leads to the rise in the global Crohns disease diagnostic and therapeutic market. Further, an improved access to pharmacological therapies in China and India and continued uptake of selected biologic brands are the main market drivers. However, major barriers to the growth of the Crohns disease include- brand erosion following the patent expiry of the market-leading therapies, the complex pathogenesis of the disease, which creates an additional challenge in demonstrating clinical efficacy during clinical development and creation of challenging environment for new market entrants due to the already established biologics market.

Market Segmentation

The market is segmented on the basis of chronic autoimmune diseases that cause intestinal inflammation: Crohns disease (CD) and ulcerative colitis (UC). Further, the classification is done on the type of procedures and drugs used. Based on procedures, the market is segmented into colonoscopy, flexible sigmoidoscopy, computerized tomography (CT), magnetic resonance imaging (MRI), capsule endoscopy, double-balloon endoscopy and small bowel imaging. Further on the basis of drug type the market is classified into antibiotics, anti-diarrheal, immune system suppressors, pain relievers, and anti-inflammatory drugs. to cope with the various symptoms associated with the disease like anti-inflammatory drugs, immunosuppressive drugs, and antipyretics to reduce pain.

Regional/Geographic Analysis

Crohns disease diagnostic and therapeutic market has enormous opportunities around the world. The major markets include- the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term. For the forecasted period the US will account for the major share, followed by the 5EU and Japan. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of Crohns disease in the region, as well as the high annual cost of therapy (ACOT) of J&J’s Stelara and the anticipated ACOT of AbbVie’s risankizumab in the US market.

Key Players

The global Crohns disease diagnostic and therapeutic market is mainly controlled by firms such as J&J’s Remicade, AbbVie’s Humira, Takeda’s alpha4beta7 inhibitor, Entyvio, Johnson & Johnson’s (J&J’s) interleukin (IL)-12/23 inhibitor, Stelara, Remicade (infliximab) and Humira (adalimumab).